Tasly Pharmaceutical Group Co., Ltd
Clinical trials sponsored by Tasly Pharmaceutical Group Co., Ltd, explained in plain language.
A Chinese pharmaceutical company known for traditional Chinese medicine and modern drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New depression pill JS1-1-01 enters key trials Results expected Dec 2026 (estimated)
- New pill shows promise against resistant cancers in early trial Results expected Dec 2026 (estimated)
- Could umbilical cord stem cells help failing hearts? Results expected Dec 2026 (estimated)
- Herbal granules aim to ease Post-Meal stomach troubles Results expected Dec 2026 (estimated)
-
New Antibody-Drug conjugate STRO-002 tested in advanced cancers
Disease control CompletedThis study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…
Phase 1/2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Herbal gout treatment shows promise in large trial
Symptom relief CompletedThis Phase 3 trial tested whether Qingzhu Granules, a traditional Chinese herbal medicine, can reduce pain from acute gouty arthritis. 472 adults with a gout flare took either the granules or a placebo for 72 hours. The main goal was to see if pain scores improved more with the r…
Phase 3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Parkinson's psychosis drug shows promise in final trial
Symptom relief CompletedThis study tested whether the drug pimavanserin can safely reduce hallucinations and delusions in people with Parkinson's disease psychosis. 248 participants took either the drug or a placebo daily for 6 weeks. The main goal was to see if symptoms improved, measured by a standard…
Phase 3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New pill could ease severe depression
Symptom relief CompletedThis phase 2 trial tested whether a new drug called JS1-1-01 can safely reduce symptoms in 267 adults with moderate to severe depression. Participants took either the drug or a placebo for 8 weeks. Researchers measured changes in depression scores to see if the drug helps.
Phase 2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC